Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage

Transplantation

Volumn 95, Issue 1, 2013, Pages 48-53

  Shimamura, Masako ^a   Seleme, Maria C ^a   Guo, Lingling ^b   Saunders, Ute ^a,b   Schoeb, Trenton R ^c   George, James F ^b   Britt, William J ^a,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Kidney; Transplantation

Indexed keywords

ALLOPHYCOCYANIN; CYCLOSPORIN; GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CELL SELECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL SELECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RENAL GRAFT DYSFUNCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; KIDNEY; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUROMEGALOVIRUS; MYELOID CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872059952     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182782efc     Document Type: Article

References (23)

1. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9: 2453.
2. Rubin RH, Tolkoff-Rubin NE, Oliver D, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985; 40: 243.
3. Gerstenkorn C, Balupuri S, Mohamed MA, et al. The impact of cytomegalovirus serology for 7-year graft survival in cadaveric kidney transplantationVthe Newcastle experience. Transplant Int 2000; 13: S372.
4. Fitzgerald JT, Gallay B, Taranto SE, et al. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation 2004; 77: 1405.
5. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
6. Lautenschlager I, Soots A, Krogerus L, et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 1997; 64: 391.
7. Lautenschlager I, Soots A, Krogerus L, et al. Time-related effects of cytomegalovirus infection on the development of chronic renal allograft rejection in a rat model. Intervirology 1999; 42: 279.
8. Inkinen K, Holma K, Soots A, et al. Expression of TGF-beta and PDGF-AA antigens and corresponding mRNAs in cytomegalovirusinfected rat kidney allografts. Transplant Proc 2003; 35: 804.
9. Soule JL, Streblow DN, Andoh TF, et al. Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles. Transplant Proc 2006; 38: 3214.
10. Shimamura M, Saunders U, Rha B, et al. Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation. Transplantation 2011; 92: 759.
11. LemstromK, Sihvola R, Bruggeman C, et al. Cytomegalovirus infectionenhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95: 2614.
12. Mannon RB, Kopp JB, Ruiz P, et al. Chronic rejection of mouse kidney allografts. Kidney Int 1999; 55: 1935.
13. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
14. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
15. Bukowski JF, Woda BA, Welsh RM. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J Virol 1984; 52: 119.
16. Venema H, Van Den Berg AP, Van Zanten C, et al. Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol 1994; 42: 188.
17. van Dam JG, Damoiseaux JG, Christiaans MH, et al. Acute primary infection with cytomegalovirus (CMV) in kidney transplant recipients results in the appearance of a phenotypically aberrant CD8+ T cell population. Microbiol Immunol 2000; 44: 1011.
18. Hancock WW, Gee D, De Moerloose P, et al. Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system. Transplantation 1985; 39: 430.
19. Vitalone MJ, Naesens M, Sigdel T, et al. The dual role of epithelial-tomesenchymal transition in chronic allograft injury in pediatric renal transplantation. Transplantation 2011; 92: 787.
20. Zhang Z, Schlachta C, Duff J, et al. Improved techniques for kidney transplantation in mice. Microsurgery 1995; 16: 103.
21. Andoh TF, Gardner MP, Bennett WM. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997; 64: 1236.
22. Kern ER, Bidanset DJ, Hartline CB, et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother 2004; 48: 4745.
23. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2011; 12: 313.